David Abel, DO
Hospitalist · Anchorage, AKNPI 1598151797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 29.8% of the total. Reporting peaked in 2024 at $174 and has fallen 69.1% since, to $54 in 2025. Among hospitalist clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$151
- Lilly USA, LLC$127
- AstraZeneca$47
- Exact Sciences$45
- Vanda Pharmaceuticals Inc.$28
- Novo Nordisk$22
- plus $87 from 5 others
What the payments were for
- Food & beverage$508100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $151 |
| Lilly USA, LLC | 3 | $127 |
| AstraZeneca | 2 | $47 |
| Exact Sciences | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Novo Nordisk | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Pfizer | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
How this compares
$508 in reported general payments places this provider in the 95th percentile of 61 hospitalist providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 11 | $1,151 |
| Tamsulosin Hcl | 25 | $405 |
| Atorvastatin Calcium | 32 | $299 |
| Omeprazole | 20 | $285 |
| Mirtazapine | 14 | $274 |
| Omega-3 Acid Ethyl Esters | 14 | $232 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $204 |
| Losartan Potassium | 20 | $191 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $178 |
| Allopurinol | 11 | $164 |
| Lisinopril | 22 | $161 |
| Sertraline Hcl | 18 | $119 |
| Metformin Hcl | 15 | $113 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Anchorage
- Leslie GonsetteAnchorage$23K
- David GrillsAnchorage$686
- Syed RahmanAnchorage$411
- Casey MapesAnchorage$200
- Shari MorganAnchorage$166
- Wesley GiffordAnchorage$153
- Aaron HaynesAnchorage$142
- Timothy BatemanAnchorage$137
- Michael MrazAnchorage$70
- Kala MausAnchorage$65
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.